|
A Deeper Look into Emerging Therapies in
the Management of Alzheimer’s Disease (AD): What Does Recent
Clinical Trial Data Have to Say?
A continuing medical education
activity provided by NAMCP and AAMCN
New Frontiers in the Treatment and Management of AD: What Managed
Care Needs to
Know about New and Emerging Therapies is a three-part webinar series
This is Part 3 of the series focusing on emerging therapies in
alzheimer’s disease
This activity is an archive from the webinar held November 18, 2020
This activity is valid from December 15, 2020 to December 1, 2022 |
Instructions for CME/NCPD: Complete the pre-test, listen to the
audio and view the slides, complete the post test, complete the
evaluation form and hit submit. You will be asked to enter your name
and email address on the pre-test, evaluation and post-test. If you
close your internet browser without completing the post test, you
will have ONE more opportunity to complete. A score of 70% must be
achieved on the post test to receive continuing education credits.
If you do not pass the post test after two attempts, you will not be
eligible to try again. Once you complete the evaluation form and
score 70% or higher on your post test, you will automatically be
given your certificate.
To print or save your certificate, you will need to click on the
“download” button and either print or save.
|
|
Audience:
This activity is intended for healthcare professionals practicing in
managed care environments.
This activity is supported by
an educational grant from
Biogen
Description:
Alzheimer’s disease is the most common form of dementia, affecting
an estimated 5 million people in the United States. It is a
cognitive disorder that includes behavioral impairment that
interferes with social and occupational functioning. Alzheimer’s
disease care costs $172 billion annually in the US alone.
Fortunately for patients with Alzheimer's disease, new and emerging
therapies, including anti-beta-amyloid (Aß) monoclonal antibodies,
are undergoing late stage clinical trials or have been submitted for
regulatory review. This program will provide strategies to overcome
challenges in the optimal treatment and management of Alzheimer’s
disease and highlight the role of managed care professionals in
making informed decisions on these new and emerging therapies that
will improve quality of life, significantly reduce clinical decline,
and minimize costs throughout the healthcare system.
Upon completion of this
activity, participants will be able to:
-
Characterize the clinical and
economic burden of Alzheimer’s disease (AD) in terms of
incidence and prevalence as well as direct and indirect costs
-
Describe various diagnostic tools
for AD and evaluate their respective benefits and disadvantages
for standardized use among network providers
-
Explore recent clinical trial data
on the efficacy, safety and mechanisms of action of new and
emerging therapies in the management of AD
-
Analyze the emerging role of
anti-beta-amyloid (Aß) monoclonal antibodies in the management
of AD for reduction in clinical decline
-
Appraise the clinical benefits of
novel therapeutics addressing neuropsychological symptoms and
disease modifying agents in the management of AD
|
Faculty: |
Richard S. Isaacson, MD
Associate Professor of Neurology
Director, Alzheimer’s Prevention Clinic
Weill Cornell Medicine
New York Presbyterian Hospital |
|
Disclosure:
|
Dr.
Isaacson serves as a consultant for Eli Lilly and
Company, Neurotrack, and 23 and Me. His presentation has
been peer reviewed for any bias. |
|
|
Planning Committee:
Bill Williams,
MD has no real or perceived financial relationships to
disclose.
Jeremy Williams has no real or perceived financial
relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no real or perceived
financial relationships to disclose.
NAMCP and/or the presenter
has copyright or has received permissions for use of
materials provided in this activity. |
Accreditation & Designation
This activity has been planned and implemented in accordance with
the accreditation requirements and policies of the Accreditation
Council for Continuing Medical Education (ACCME) through the joint
providership of the National Association of Managed Care Physicians
(NAMCP) and American Association of Managed Care Nurses (AAMCN). The
National Association of Managed Care Physicians is accredited by the
ACCME to provide continuing medical education for physicians.
NAMCP designates this enduring material for a maximum of 1 AMA
PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their
participation in the activity.
The American Association of Managed Care Nurses is accredited as a
provider of nursing continuing professional development by the
American Nurses Credentialing Center's Commission on Accreditation.
Nurses who complete this activity and achieve a passing score will
receive 1 hour in nursing continuing professional development.
This activity has been approved by the American Board of Managed
Care Nursing for 1.0 contact hours toward CMCN recertification
requirements.
This activity is supported by an educational grant from
Biogen
NAMCP and/or this website does not
provide medical advice, diagnosis or treatment. NAMCP does not
endorse or imply endorsement of the content on any linked website.
This website is to be used as an informational resource. With any
health related concern, consult with your physician or healthcare
professional.
Click Here To Continue |